73 material Form 8-K filings that 66 companies we cover made with the SEC in January 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Elevance Health reported fourth-quarter and full-year 2023 results in a press release furnished under Item 2.02 of this 8-K. Quarterly operating revenue rose 7.0% to $42.5 billion and GAAP diluted EPS rose 1.1% to $3.63, while the company set a full-year 2024 GAAP diluted EPS outlook of greater than $34.29, compared with $25.22 for 2023, and raised its quarterly dividend 10.1% to $1.63 per share.
4Q 2023 operating revenue $42.5 billion, up 7.0%; GAAP diluted EPS $3.63, up 1.1%; adjusted diluted EPS $5.62, up 15.2%
FY 2024 GAAP diluted EPS outlook greater than $34.29; adjusted diluted EPS outlook greater than $37.10, versus FY 2023 GAAP diluted EPS of $25.22
Quarterly dividend increased 10.1% to $1.63 per share
4Q 2023 operating margin was 3.0%, down from 3.2% in 4Q 2022
Agilysys reported fiscal 2024 third-quarter results for the period ended December 31, 2023, with total net revenue up 21.3% to a record $60.6 million and adjusted EBITDA up to $11.8 million from $8.1 million a year earlier. The company raised its fiscal 2024 Adjusted EBITDA expectation to 15% of revenue and reiterated its full-year revenue guidance of $235 million to $238 million. GAAP net income of $76.9 million was boosted by a $65.1 million release of tax valuation allowances.
Total net revenue rose 21.3% to $60.6 million from $49.9 million; subscription revenue grew 29.9% year-over-year.
GAAP net income attributable to common shareholders was $76.9 million, or $2.85 per diluted share, versus $0.13 a year earlier, including a $65.1 million valuation allowance release.
Adjusted diluted EPS was $0.35 versus $0.26; adjusted EBITDA was $11.8 million versus $8.1 million.
Fiscal 2024 Adjusted EBITDA guidance raised to 15% of revenue; revenue guidance of $235 million to $238 million reiterated.
InterDigital released unaudited preliminary results for the quarter ended December 31, 2023, and an initial first-quarter 2024 outlook. Expected Q4 net income of about $34 million and diluted EPS of about $1.20 are both above the prior expectations, mainly due to an expected release of a valuation allowance against deferred tax assets in certain foreign jurisdictions. The company warned that final results could differ materially, with final figures due February 15, 2024.
Q4 2023 revenue expected at about $105 million, in line with prior guidance
Q4 net income expected at about $34 million, above the prior $18 million to $21 million; diluted EPS about $1.20 vs. prior $0.70 to $0.80
Q4 operating expenses expected at about $81 million, up from $77 million to $79 million due to higher litigation costs and performance-based compensation
Q1 2024 outlook: revenue $245 million to $255 million and net income $70 million to $85 million; final results due February 15, 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.